SCHEMBL3813005

SCHEMBL3813005

CC(C)(CCl)CON=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5159191 0.84 KMT2A (0.45)
SCHEMBL13937956 0.75
SCHEMBL28064327 0.74
SCHEMBL3679547 0.73
SCHEMBL5449927 0.69 KMT2A (0.41)
SCHEMBL5276093 0.65 MAPK1 (0.31)
SCHEMBL6141334 0.65
SCHEMBL7629878 0.65
SCHEMBL1975714 0.64
SCHEMBL16010715 0.63 SERPINE1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054527-A1 Administration of capsaicinoids ALGORX (US) 2009-02-26 US claimed
EP-1587506-A4 ADMINISTRATION OF CAPSAICINOIDS ALGORX (US) 2006-05-24 EP claimed
EP-1587506-A2 ADMINISTRATION OF CAPSAICINOIDS Algorx (US) 2005-10-26 EP claimed
US-20040156931-A1 Administration of capsaicinoids ALGORX 2004-08-12 US claimed
WO-2004056305-A2 ADMINISTRATION OF CAPSAICINOIDS ALGORX (US) 2004-07-08 WO claimed
US-5646181-A ORGANIC NITRITE COMPOUNDS RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1997-07-08 US claimed
US-5489610-A TREATING CONDITIONS SUCH AS ANGINA PECTORIS, ISCHEMIC DISEASES, CONGESTIVE HEART FAILURE, CONTROLLING HYPERTENSION AND IMPOTENCE IN MALE PATIENTS RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 1996-02-06 US claimed
EP-0604642-A1 SUSTAINED RELEASE ORGANIC NITRITE THERAPY BAKER NORTON PHARMACEUTICALS, INC. (US) 1994-07-06 EP claimed
WO-1994001103-A1 SUSTAINED RELEASE ORGANIC NITRITE THERAPY BAKER NORTON PHARMACEUTICALS, INC. (US) 1994-01-20 WO claimed
US-20090117167-A1 Injectable capsaicin with vasocontrictor adjunctive agent ALGORX (US) 2009-05-07 US disclosed
US-20090118242-A1 Injectable capsaicin with non-steroidal anti-inflammatory adjunctive agent ALGORX (US) 2009-05-07 US disclosed
US-20090111792-A1 Injectable capsaicin with tricyclic antidepressant adjunctive agent ALGORX (US) 2009-04-30 US disclosed
US-20090062359-A1 Injectable capsaicin with non-local anesthetic sodium channel-blocker adjunctive agent ALGORX (US) 2009-03-05 US disclosed
US-20090054527-A1 Administration of capsaicinoids ALGORX (US) 2009-02-26 US disclosed
EP-0783283-A4 METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE BAKER NORTON PHARMA (US) 2000-05-10 EP disclosed
EP-0783283-A1 METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE BAKER NORTON PHARMACEUTICALS, INC. (US) 1997-07-16 EP disclosed
WO-1996034583-A1 METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE BAKER NORTON PHARMACEUTICALS, INC. (US) 1996-11-07 WO disclosed
US-5489610-A TREATING CONDITIONS SUCH AS ANGINA PECTORIS, ISCHEMIC DISEASES, CONGESTIVE HEART FAILURE, CONTROLLING HYPERTENSION AND IMPOTENCE IN MALE PATIENTS RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 1996-02-06 US disclosed
EP-0604642-A1 SUSTAINED RELEASE ORGANIC NITRITE THERAPY BAKER NORTON PHARMACEUTICALS, INC. (US) 1994-07-06 EP disclosed
WO-1994001103-A1 SUSTAINED RELEASE ORGANIC NITRITE THERAPY BAKER NORTON PHARMACEUTICALS, INC. (US) 1994-01-20 WO disclosed